Ignite Creation Date:
2024-05-05 @ 11:57 PM
Last Modification Date:
2024-10-26 @ 10:42 AM
Study NCT ID:
NCT01454531
Status:
COMPLETED
Last Update Posted:
2015-03-06
First Post:
2011-10-13
Brief Title:
An Open Trial to Assess the Tolerability of AVANZ Phleum Pratense Immunotherapy
Sponsor:
ALK-Abelló AS
Organization:
ALK-Abelló AS
Study Overview
Official Title:
An Open Trial to Assess the Tolerability of AVANZ Phleum Pratense Immunotherapy
Status:
COMPLETED
Status Verified Date:
2015-02
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The purpose of this study is to assess the tolerability of AVANZ
Detailed Description:
To assess the tolerability of the up-dosing phase of AVANZ Phleum pratense The frequency of patients with adverse reactions will be the study primary endpoint
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None